These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
571 related articles for article (PubMed ID: 25682993)
61. Relationship between mucosal healing by tacrolimus and relapse of refractory ulcerative colitis: a retrospective study. Ito A; Murasugi S; Omori T; Nakamura S; Tokushige K BMC Gastroenterol; 2020 Jun; 20(1):203. PubMed ID: 32590945 [TBL] [Abstract][Full Text] [Related]
62. Efficacy of cyclosporin with corticotropin for refractory ulcerative colitis. Okamura S; Aoki H; Ohashi S; Urano F; Shimodaira M; Kanamori S; Ishikawa H; Segawa K Hepatogastroenterology; 2003; 50(49):91-4. PubMed ID: 12629999 [TBL] [Abstract][Full Text] [Related]
63. Oral tacrolimus treatment of severe colitis in children. Bousvaros A; Kirschner BS; Werlin SL; Parker-Hartigan L; Daum F; Freeman KB; Balint JP; Day AS; Griffiths AM; Zurakowski D; Ferry GD; Leichtner AM J Pediatr; 2000 Dec; 137(6):794-9. PubMed ID: 11113835 [TBL] [Abstract][Full Text] [Related]
64. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Sandborn WJ; Hanauer S; Lichtenstein GR; Safdi M; Edeline M; Scott Harris M Aliment Pharmacol Ther; 2011 Oct; 34(7):747-56. PubMed ID: 21848857 [TBL] [Abstract][Full Text] [Related]
65. Appropriate Timing of Discontinuation of Tacrolimus Therapy for Refractory Ulcerative Colitis. Matsumoto S; Otake H; Sekine M; Uehara T; Miyatani H; Mashima H Clin Drug Investig; 2019 Aug; 39(8):737-744. PubMed ID: 31065933 [TBL] [Abstract][Full Text] [Related]
66. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease. Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527 [TBL] [Abstract][Full Text] [Related]
67. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Fellermann K; Ludwig D; Stahl M; David-Walek T; Stange EF Am J Gastroenterol; 1998 Oct; 93(10):1860-6. PubMed ID: 9772045 [TBL] [Abstract][Full Text] [Related]
68. Assessment of Endoscopic Mucosal Healing of Ulcerative Colitis Using Linked Colour Imaging, a Novel Endoscopic Enhancement System. Uchiyama K; Takagi T; Kashiwagi S; Toyokawa Y; Tanaka M; Hotta Y; Dohi O; Okayama T; Yoshida N; Katada K; Kamada K; Ishikawa T; Handa O; Konishi H; Kishimoto M; Yagi N; Naito Y; Itoh Y J Crohns Colitis; 2017 Aug; 11(8):963-969. PubMed ID: 28333209 [TBL] [Abstract][Full Text] [Related]
69. Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes. Pandey A; Achrafie L; Kodjamanova P; Tencer T; Kumar J Curr Med Res Opin; 2022 Sep; 38(9):1531-1541. PubMed ID: 35608153 [TBL] [Abstract][Full Text] [Related]
70. Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. Narula N; Aruljothy A; Alshahrani AA; Fadida M; Al-Saedi M; Marshall JK; Rubin DT; Christensen B Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1676-1682. PubMed ID: 33131108 [TBL] [Abstract][Full Text] [Related]
71. Potential utility of a new ulcerative colitis segmental endoscopic index combining disease severity and the extent of inflammation. Suzuki Y; Uchiyama K; Kato M; Matsuo K; Nakagawa T; Kishikawa H; Kimura N; Kasanuki J; Ino S J Clin Gastroenterol; 2015; 49(5):401-6. PubMed ID: 25127112 [TBL] [Abstract][Full Text] [Related]
72. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. Ziring DA; Wu SS; Mow WS; Martín MG; Mehra M; Ament ME J Pediatr Gastroenterol Nutr; 2007 Sep; 45(3):306-11. PubMed ID: 17873742 [TBL] [Abstract][Full Text] [Related]
73. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience. Nuki Y; Esaki M; Asano K; Maehata Y; Umeno J; Moriyama T; Nakamura S; Matsumoto T; Kitazono T Scand J Gastroenterol; 2016; 51(6):700-5. PubMed ID: 26818468 [TBL] [Abstract][Full Text] [Related]
74. Medium to long-term efficacy and safety of oral tacrolimus in moderate to severe steroid refractory ulcerative colitis. Olmedo Martín RV; Amo Trillo V; González Grande R; Jiménez Pérez M Rev Esp Enferm Dig; 2017 Aug; 109(8):559-565. PubMed ID: 28617029 [TBL] [Abstract][Full Text] [Related]
75. Timing for dose-down of 5-ASA depends on mucosal status with ulcerative colitis. Takahashi F; Tominaga K; Kanamori A; Takenaka K; Hoshino A; Sugaya T; Nakano M; Hiraishi H Scand J Gastroenterol; 2016 Jul; 51(7):827-34. PubMed ID: 26853910 [TBL] [Abstract][Full Text] [Related]
76. Combined Histo-endoscopic Remission but not Endoscopic Healing Alone in Ulcerative Colitis is Associated with a Mucosal Transcriptional Profile Resembling Healthy Mucosa. Hernández-Rocha C; Nayeri S; Turpin W; Steel M; Borowski K; Stempak JM; Conner J; Silverberg MS J Crohns Colitis; 2022 Aug; 16(7):1020-1029. PubMed ID: 34999763 [TBL] [Abstract][Full Text] [Related]
77. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Sandborn WJ; Colombel JF; D'Haens G; Van Assche G; Wolf D; Kron M; Lazar A; Robinson AM; Yang M; Chao JD; Thakkar R Aliment Pharmacol Ther; 2013 Jan; 37(2):204-13. PubMed ID: 23173821 [TBL] [Abstract][Full Text] [Related]
78. Efficacy of Therapeutic Intervention for Patients With an Ulcerative Colitis Mayo Endoscopic Score of 1. Fukuda T; Naganuma M; Sugimoto S; Ono K; Nanki K; Mizuno S; Kimura K; Mutaguchi M; Nakazato Y; Takabayashi K; Inoue N; Ogata H; Iwao Y; Kanai T Inflamm Bowel Dis; 2019 Mar; 25(4):782-788. PubMed ID: 30265308 [TBL] [Abstract][Full Text] [Related]
79. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Arijs I; De Hertogh G; Lemmens B; Van Lommel L; de Bruyn M; Vanhove W; Cleynen I; Machiels K; Ferrante M; Schuit F; Van Assche G; Rutgeerts P; Vermeire S Gut; 2018 Jan; 67(1):43-52. PubMed ID: 27802155 [TBL] [Abstract][Full Text] [Related]
80. Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy. Zezos P; Patsiaoura K; Nakos A; Mpoumponaris A; Vassiliadis T; Giouleme O; Pitiakoudis M; Kouklakis G; Evgenidis N Colorectal Dis; 2014 Dec; 16(12):O420-30. PubMed ID: 25040651 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]